Navigation Links
NuVasive to Present at Canaccord Adams Musculoskeletal Conference
Date:2/17/2009

SAN DIEGO, Feb. 17 /PRNewswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NUVA), a medical device company focused on developing products for minimally disruptive surgical treatments for the spine, announced today that Patrick Williams, Vice President, Finance, is scheduled to present at the Canaccord Adams Musculoskeletal Conference at the University of Nevada in Las Vegas, Nevada on Tuesday, February 24, 2009 at 8:20 a.m. PT.

A live Web cast of the presentation will be available online from the investor relations page of the Company's corporate Web site at www.nuvasive.com. After the live Web cast, the presentation will remain available on NuVasive's Web site, www.nuvasive.com, for 30 days.

About NuVasive

NuVasive is a medical device company focused on the design, development and marketing of products for the surgical treatment of spine disorders. The Company's product portfolio is focused on applications in the over $4.6 billion U.S. spine fusion market. The Company's current principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery, or MAS(R), as well as a growing offering of cervical and motion preservation products.

The MAS platform offers advantages for both patients and surgeons such as reduced surgery and hospitalization time and faster recovery. MAS combines three categories of current product offerings: NeuroVision(R) a proprietary software-driven nerve avoidance system; MaXcess(R) a unique split-blade design retraction system; and specialized implants, like SpheRx(R) and CoRoent(R), that collectively minimize soft tissue disruption during spine surgery while allowing maximum visualization and surgical reproducibility. NuVasive's product offering is also focused on cervical internal fixation products and its R&D pipeline emphasizes both MAS and motion preservation. NuVasive's Biologic product portfolio includes FormaGraft(R), Osteocel(R) Plus, and the Progentix products, all of which are intended to facilitate fusion and complement the core fixation products.

NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties that could cause actual growth and results to differ materially include, but are not limited to: the uncertain process of seeking regulatory approval or clearance for NuVasive's products or devices, including risks that such process could be significantly delayed; the possibility that the FDA may require significant changes to NuVasive's products or clinical studies; the risk that products may not perform as intended and may therefore not achieve commercial success; the risk that competitors may develop superior products or may have a greater market position enabling more successful commercialization; the risk that additional clinical data may call into question the benefits of NuVasive's products to patients, hospitals and surgeons; and other risks and uncertainties more fully described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

    Contact:                            Investors:
    Kevin C. O'Boyle                    Patrick F. Williams
    EVP & Chief Financial Officer       Vice President, Finance
    NuVasive, Inc.                      NuVasive, Inc.
    858-909-1998                        858-638-5511
    investorrelations@nuvasive.com      investorrelations@nuvasive.com

    Media:
    Jason Rando
    The Ruth Group
    646-536-7025
    jrando@theruthgroup.com


'/>"/>
SOURCE NuVasive, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. NuVasive to Present at ROTH 21st Annual OC Growth Stock Conference
2. NuVasive Announces Preliminary Unaudited Full Year 2008 Financial Results
3. NuVasive to Present at 27th Annual J.P. Morgan Healthcare Conference
4. NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference
5. NuVasive Announces Patent Infringement Complaint Brought by Medtronic Sofamor Danek
6. NuVasive to Present at Goldman Sachs 29th Annual Global Healthcare Conference
7. NuVasive Acquires First Stem Cell Bone Graft Substitute
8. NuVasive Reports First Quarter 2008 Financial Results
9. NuVasive Prices $200 Million Convertible Senior Notes Due 2013
10. NuVasive to Offer $200 Million Convertible Senior Notes Due 2013
11. NuVasive Announces Preliminary Unaudited Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... ... 17, 2017 , ... For the first time, International Scholarship ... exhibit floor for the 2017 HIMSS Conference & Exhibition at the ... more than 40,000 healthcare industry professionals are expected at the conference, where they ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the company’s booth ... most widely used electronic patient signatures solution in healthcare . , Since ...
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... premier sponsor and exhibitor at Molecular Medicine Tri-Conference February 20 – 22 in ... Wednesday, Inspirata will showcase its anatomic and molecular pathology workflow solution, as well ...
(Date:2/16/2017)... York, New York (PRWEB) , ... February 17, ... ... work and determination. After what took over 10 years of research, development and ... technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ingredients ...
Breaking Medicine News(10 mins):
(Date:2/19/2017)... ORLANDO, Fla. , Feb. 18, 2017 /PRNewswire/ ... announced that positive Phase 1 clinical data for Nektar,s ... carcinoma (RCC) were presented at ASCO GU 2017.  NKTR-214 ... cancer-fighting T cells and Natural Killer (NK) cell abundance ... PD-1 on these immune cells.  The results were presented ...
(Date:2/17/2017)... Feb. 17, 2017  Ethicon, Inc. today announced ... a privately held medical device company that manufactures ... System, a novel minimally invasive device for the ... Medical will enable Ethicon to offer patients a ... Nissen fundoplication surgical procedure. 1 ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: